New Arthritis Drug Combo Increased Methotrexate Retention
A study suggests a dual-drug treatment could improve medication efficiency in patients with rheumatoid arthritis.
Updated on Oct. 7, 2026 in Arthritis
Live Poll
Should medical research prioritize early biomarker data when evaluating potential new treatment options?
Researchers have reported phase 1b results for NovoBioJect, a combination therapy for rheumatoid arthritis that combines low-dose methotrexate with novobiocin. This preliminary study found that the drug increased the retention of methotrexate in immune cells, a finding that will undergo further investigation in larger clinical trials.
Why it matters
Improving methotrexate retention could potentially enhance the efficacy of this standard arthritis medication without the need for higher, more toxic doses. This study marks a step toward evaluating whether this combination can optimize treatment for patients currently managing rheumatoid arthritis.
This phase 1b study of 12 rheumatoid arthritis patients showed a 38% increase in methotrexate polyglutamates (P=0.009) compared to methotrexate alone. Because the sample size is small and the trial is preliminary, these results require validation in larger populations.
The players
Amplio Pharma
A pharmaceutical developer focused on creating advanced drug delivery and combination therapies for chronic autoimmune conditions.
The details
NovoBioJect works by utilizing low-dose novobiocin to inhibit the ABCG2 efflux transporter, which otherwise pumps methotrexate out of immune cells. By blocking this transport pathway, the drug allows for higher concentrations of methotrexate to remain active within the cells. Participants in the study received subcutaneous novobiocin at 80mg, 150mg, or 200mg doses, with only mild injection-site reactions reported as a side effect.
Timeline
October 2026: Phase 1b results were reported by Amplio Pharma.
2026: The full phase 1b dataset was presented at ACR Convergence.
2027: Amplio Pharma expects to begin a phase 2a clinical study.
Health Landscape
This development aligns with the latest clinical data presented at the ACR Convergence research meetings regarding advancements in drug delivery. It represents a shift from simply increasing dosages of traditional disease-modifying antirheumatic drugs toward optimizing intracellular retention.
While this drug candidate is currently in early-stage testing, these findings reflect the importance of medication consistency in managing rheumatoid arthritis. Discuss any concerns regarding your current methotrexate regimen or potential side effects with your rheumatologist.
The takeaway
This preliminary study demonstrates that combining novobiocin with methotrexate may help immune cells hold onto medication more effectively. Patients should continue their current prescribed treatment plans and consult their physician regarding future developments in arthritis therapies.
What happens next
Amplio Pharma intends to initiate a phase 2a study involving 100 newly diagnosed rheumatoid arthritis patients in 2027.
Further reading
For more information on the current landscape of Arthritis care, visit our comprehensive resource section.
Source note: This article includes information reported by Pharmafile.
Live Poll
Should medical research prioritize early biomarker data when evaluating potential new treatment options?
